References
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
- Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007;12:38-50
- Funaioli C, Longobardi C, Martoni AA. The impact of chemotherapy on overall survival and quality of life of patients with metastatic colorectal cancer: a review of phase III trials. J Chemother 2008;20:14-27
- Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
- Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
- Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8
- Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
- Genentech Inc. Avastin® (bevacizumab) [prescribing information]. http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf; 2011
- Bristol-Myers Squibb. Erbitux® (cetuximab) [prescribing information]. http://packageinserts.bms.com/pi/pi_erbitux.pdf; 2011
- Amgen Inc. Vectibix® (Panitumumab) [prescribing information]. http://pi.amgen.com/united_states/vectibix/vectibix_pi.pdf; 2011
- Hurwitz HI, Yi J, Ince W, et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009;14:22-8
- Lang K, Lines LM, Lee DW, et al. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data. Clin Gastroenterol Hepatol 2009;7:198-204
- Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin Ther 2007;29:2256-67
- Starling N, Tilden D, White J, et al. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 2007;96:206-12
- Tappenden P, Jones R, Paisley S, et al. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 2007;43:2487-94
- Tappenden P, Jones R, Paisley S, et al. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007;11:1-128, iii-iv
- Ramsey SD, Martins RG, Blough DK, et al. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care 2008;14:297-306
- Saif MW, Shi N, Zelt S. Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. World J Gastroenterol 2009;15:4415-22
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
- Wong YN, Meropol NJ, Speier W, et al. Cost implications of new treatments for advanced colorectal cancer. Cancer 2009;115:2081-91
- Delea TE, Vera-Llonch M, Edelsberg JS, et al. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. Value Health 2002;5:35-43
- Paramore LC, Thomas SK, Knopf KB, et al. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer 2006;6:52-8